

Resource Summary Report

Generated by [RRID](#) on Aug 19, 2026

[pLX302](#)

RRID:Addgene_25896

Type: Plasmid

Proper Citation

RRID:Addgene_25896

Plasmid Information

URL: <http://www.addgene.org/25896>

Proper Citation: RRID:Addgene_25896

Bacterial Resistance: Chloramphenicol and Ampicillin

Defining Citation: [PMID:21706014](#)

Vector Backbone Description: Backbone Size:9573; Vector Backbone:pLKO; Vector Types:Mammalian Expression, Lentiviral, Gateway Cloning; Bacterial Resistance:Chloramphenicol and Ampicillin

Comments: There is a C-terminal V5 tag followed by a Stop codon directly after the Gateway sequence.

Plasmid Name: pLX302

Record Creation Time: 20220422T222115+0000

Record Last Update: 20260815T081246+0000

Ratings and Alerts

No rating or validation information has been found for pLX302.

No alerts have been found for pLX302.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 55 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lei G, et al. (2026) Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. *Cell*.

Nagata H, et al. (2026) CDKAL1 dysfunction impairs lysine codon translation in podocytes and accelerates chronic kidney disease. *The EMBO journal*, 45(9), 3206.

Jia A, et al. (2026) Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD⁺ to eradicate KRAS-driven AML. *Cell metabolism*, 38(6), 1113.

Lin W, et al. (2025) Transdifferentiation of tongue muscle cells into cancer-associated fibroblasts in response to tongue squamous cell carcinoma. *Nature communications*, 16(1), 6753.

Ibrahim NK, et al. (2025) SOD2 is a regulator of proteasomal degradation promoting an adaptive cellular starvation response. *Cell reports*, 44(4), 115434.

Marohl T, et al. (2025) PCSK5M452I is a recessive hypomorph exclusive to MCF10DCIS.com cells. *Molecular cancer research : MCR*.

Magri Z, et al. (2024) CD14 is a decision-maker between Fas-mediated death and inflammation. *Cell reports*, 43(9), 114685.

Asanoma K, et al. (2024) The BHLHE40?PPM1F?AMPK pathway regulates energy metabolism and is associated with the aggressiveness of endometrial cancer. *The Journal of biological chemistry*, 300(3), 105695.

Delgado M, et al. (2024) Testis-specific serine kinase 6 (TSSK6) is abnormally expressed in colorectal cancer and promotes oncogenic behaviors. *The Journal of biological chemistry*, 300(6), 107380.

Liu X, et al. (2023) Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. *Nature cell biology*, 25(3), 404.

Worboys JD, et al. (2023) TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation. *Nature communications*, 14(1), 5016.

Belhadj S, et al. (2023) NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(2), 422.

Bakht MK, et al. (2023) Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. *Nature cancer*, 4(5), 699.

Zelceski A, et al. (2023) MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells. *Cell reports*, 42(5), 112484.

Ladewig E, et al. (2022) The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation. *Cancer research*, 82(12), 2269.

Rukhlenko OS, et al. (2022) Control of cell state transitions. *Nature*, 609(7929), 975.

Sun T, et al. (2022) MESH1 knockdown triggers proliferation arrest through TAZ repression. *Cell death & disease*, 13(3), 221.

Reggiardo RE, et al. (2022) Mutant KRAS regulates transposable element RNA and innate immunity via KRAB zinc-finger genes. *Cell reports*, 40(3), 111104.

Weeks AM, et al. (2021) Mapping proteolytic neo-N termini at the surface of living cells. *Proceedings of the National Academy of Sciences of the United States of America*, 118(8).

Prawira A, et al. (2021) Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor. *Journal of cancer research and clinical oncology*, 147(10), 2955.